- freely available
Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis
AbstractThe objective of this meta-analysis was to determine the diagnostic accuracy of circulating microRNA-155 (miR-155) for breast cancer (BC). PubMed, Embase, EBSCO (ASP/BSP), Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched up to 30 January 2014 for eligible studies. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) was employed to assess the quality of the included studies. Meta-analysis were performed in Meta-Disc 1.4 and Stata 12.0. Three studies with total 184 BC patients and 75 control individuals were included in this meta-analysis. All of the included studies are of high quality (QUADAS scores 12 or 13). The summary estimates revealed that the pooled sensitivity is 79% (95% confidence interval (CI): 72%–84%) and the specificity is 85% (95% CI: 75%–92%), for the diagnosis of breast cancer. In addition, the area under the summary ROC curve (AUC) is 0.9217. The current evidence suggests that circulating miR-155 has the potential diagnostic value with a high sensitivity and specificity for BC. More prospective studies on the diagnostic value of circulating miR-155 for BC are needed in the future.
- Supplementary File 1:
Supplementary Material (PDF, 19 KB)
Share & Cite This Article
Wang, F.; Hou, J.; Jin, W.; Li, J.; Yue, Y.; Jin, H.; Wang, X. Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis. Molecules 2014, 19, 6282-6293.View more citation formats
Wang F, Hou J, Jin W, Li J, Yue Y, Jin H, Wang X. Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis. Molecules. 2014; 19(5):6282-6293.Chicago/Turabian Style
Wang, Faliang; Hou, Jinchao; Jin, Wei; Li, Jiaqiu; Yue, Yongfang; Jin, Hongchuan; Wang, Xian. 2014. "Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis." Molecules 19, no. 5: 6282-6293.